High platelet reactivity (HPR) on clopidogrel and chronic kidney disease (CKD) are recognized as potent risk factors for adverse outcomes in patients suffering coronary artery disease (CAD) and undergoing percutaneous coronary intervention (PCI). However, conclusive evidence regarding their reciprocal interaction and the consequent impact on clinical events is still lacking.

Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis

Mangiacapra, Fabio;Nusca, Annunziata;Melfi, Rosetta;Ussia, Gian P;Grigioni, Francesco
2022-01-01

Abstract

High platelet reactivity (HPR) on clopidogrel and chronic kidney disease (CKD) are recognized as potent risk factors for adverse outcomes in patients suffering coronary artery disease (CAD) and undergoing percutaneous coronary intervention (PCI). However, conclusive evidence regarding their reciprocal interaction and the consequent impact on clinical events is still lacking.
chronic kidney disease
clopidogrel
coronary artery disease
high platelet reactivity
Blood Platelets
Clopidogrel
Female
Humans
Male
Platelet Aggregation Inhibitors
Prevalence
Risk Factors
Treatment Outcome
Coronary Artery Disease
Myocardial Infarction
Percutaneous Coronary Intervention
Renal Insufficiency, Chronic
Thrombosis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12610/67131
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact